View Clinical Trial (Medical Research Study)

Pilot Study: The Role of Migration Inhibitory Factor (MIF) in Spinal Cord Injury - NCT00919581-11030(Clinical Trial 297736)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Manhasset
State:  
NY
Zip Code: 11030
Conditions: Spinal Cord Injury
Purpose: The purpose of this study is to evaluate substances that may be present in the blood after a spinal cord injury (SCI). Specifically, the study will evaluate the presence and levels of a protein, macrophage migration inhibitory factor (MIF), in the blood of patients who have had a SCI. Blood samples from patients who have had a SCI and healthy individuals will be studied to measure MIF levels. MIF is released by cells and has a specific effect on the way cells behave, communicate and work together. In several other medical conditions, MIF is known to increase inflammation in the body. By comparing blood samples from spinal cord injury patients and normal healthy individuals, the investigators will try to find out if MIF levels are increased in people with SCI. Investigators will also use these samples to see if the biological activities of MIF can be reduced in a test tube by adding other substances to the blood samples. It is hoped that this study of MIF will help improve the treatment of SCI in the future. We hope to enroll a total of 75 subjects in this study (50 with spinal cord injury, 25 healthy individuals).
Study summary: During the study visit the investigator will collect basic biographical information and health information from the subjects medical record. The subjects will also have blood drawn (approximately 1 tablespoon) once in the morning and once in the evening. Whenever possible, this blood will be collected at the time of a regularly scheduled blood draw so no extra "stick" will be needed. It is possible if the doctor treating the SCI orders a spinal tap be done as a part of routine medical care, that one or two drops of the fluid that surrounds the spinal cord that would have been discarded, will instead be kept for analysis
Criteria: Inclusion Criteria: SCI Subject Inclusion Criteria: To be eligible for prospective enrollment, subjects are required to meet the following inclusion criteria: - ≥18 years of age - History SCI (acute or chronic): All American Spinal Injury Association (ASIA) classifications A-E and all levels. Healthy Control Subject Inclusion Criteria: To be eligible for prospective enrollment, healthy control subjects are required to meet the following inclusion criteria: - ≥18 years of age - The absence of any current or previous medical conditions (confirmed by complete medical/surgical history, brief physical examination, laboratory blood tests, including complete blood count and comprehensive metabolic profile) Exclusion Criteria: SCI Subject Exclusion Criteria: To be eligible for prospective enrollment, subjects are required to not meet the following exclusion criteria: - < 18 years of age - No known SCI - Concurrent infection such as UTI Healthy Control Subject Exclusion Criteria: To be eligible for prospective enrollment, healthy control subjects are required to not meet the following exclusion criteria: - < 18 years of age - Current or previous medical conditions
Study is available at: General CLinical Research Center
Manhasset, NY 11030
United States

Primary Contact:
Gulru Sharifova
Email: gsharifo@nshs.edu
Phone: 516-562-1012

Secondary Contact:
Gulru Sharifova
Email: gsharifo@nshs.edu
Phone: 516-562-1012
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.